{
  "$schema": "folio-library-document/v1",
  "id": "10665-360869",
  "title": "Guidelines on long-acting injectable cabotegravir for HIV prevention",
  "variant": "pdf",
  "pages": 40,
  "tocSource": "outline",
  "tocMethod": null,
  "toc": [
    {
      "level": 1,
      "title": "Executive summary",
      "number": null,
      "page": 11,
      "pageLabel": "ix",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-003-executive-summary"
    },
    {
      "level": 2,
      "title": "Purpose",
      "number": null,
      "page": 11,
      "pageLabel": "ix",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-004-purpose"
    },
    {
      "level": 3,
      "title": "Guideline development methodology",
      "number": null,
      "page": 11,
      "pageLabel": "ix",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-005-guideline-development-methodology"
    },
    {
      "level": 4,
      "title": "Implications for implementation",
      "number": null,
      "page": 12,
      "pageLabel": "x",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-006-implications-for-implementation"
    },
    {
      "level": 2,
      "title": "\u0003Introduction",
      "number": "1",
      "page": 13,
      "pageLabel": "1",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-007-1-introduction"
    },
    {
      "level": 3,
      "title": "\u0003Background",
      "number": "1.1",
      "page": 13,
      "pageLabel": "1",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-008-11-background"
    },
    {
      "level": 4,
      "title": "\u0003Guiding principles",
      "number": "1.3",
      "page": 15,
      "pageLabel": "3",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-010-13-guiding-principles"
    },
    {
      "level": 4,
      "title": "\u0003Objective and intended audience",
      "number": "1.2",
      "page": 14,
      "pageLabel": "2",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-009-12-objective-and-intended-audience"
    },
    {
      "level": 2,
      "title": "\u0003Methods for guideline development",
      "number": "2",
      "page": 16,
      "pageLabel": "4",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-011-2-methods-for-guideline-development"
    },
    {
      "level": 2,
      "title": "\u0003Rationale and supporting evidence",
      "number": "3",
      "page": 17,
      "pageLabel": "5",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-012-3-rationale-and-supporting-evidence"
    },
    {
      "level": 3,
      "title": "Summary of review findings",
      "number": "3.1",
      "page": 17,
      "pageLabel": "5",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-013-31-summary-of-review-findings"
    },
    {
      "level": 4,
      "title": "Feasibility",
      "number": "3.4",
      "page": 22,
      "pageLabel": "10",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-016-34-feasibility"
    },
    {
      "level": 4,
      "title": "Values and preferences",
      "number": "3.3",
      "page": 21,
      "pageLabel": "9",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-015-33-values-and-preferences"
    },
    {
      "level": 4,
      "title": "Cost–effectiveness",
      "number": "3.2",
      "page": 20,
      "pageLabel": "8",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-014-32-costeffectiveness"
    },
    {
      "level": 3,
      "title": "Equity",
      "number": "3.5",
      "page": 22,
      "pageLabel": "10",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-017-35-equity"
    },
    {
      "level": 3,
      "title": "Rationale for recommendation",
      "number": "3.6",
      "page": 22,
      "pageLabel": "10",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-018-36-rationale-for-recommendation"
    },
    {
      "level": 2,
      "title": "\u0003Implementation considerations",
      "number": "4",
      "page": 24,
      "pageLabel": "12",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-019-4-implementation-considerations"
    },
    {
      "level": 3,
      "title": "HIV testing and other testing requirements",
      "number": "4.1",
      "page": 24,
      "pageLabel": "12",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-020-41-hiv-testing-and-other-testing-requirements"
    },
    {
      "level": 4,
      "title": "Service delivery",
      "number": "4.2",
      "page": 26,
      "pageLabel": "14",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-021-42-service-delivery"
    },
    {
      "level": 3,
      "title": "Comprehensive services",
      "number": "4.3",
      "page": 27,
      "pageLabel": "15",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-022-43-comprehensive-services"
    },
    {
      "level": 3,
      "title": "Offering a choice of PrEP options",
      "number": "4.4",
      "page": 27,
      "pageLabel": "15",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-023-44-offering-a-choice-of-prep-options"
    },
    {
      "level": 3,
      "title": "Involving communities",
      "number": "4.5",
      "page": 27,
      "pageLabel": "15",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-024-45-involving-communities"
    },
    {
      "level": 3,
      "title": "Creating awareness and demand",
      "number": "4.6",
      "page": 27,
      "pageLabel": "15",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-025-46-creating-awareness-and-demand"
    },
    {
      "level": 3,
      "title": "Adherence support and discontinuation",
      "number": "4.7",
      "page": 28,
      "pageLabel": "16",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-026-47-adherence-support-and-discontinuation"
    },
    {
      "level": 4,
      "title": "Training and support for providers",
      "number": "4.8",
      "page": 28,
      "pageLabel": "16",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-027-48-training-and-support-for-providers"
    },
    {
      "level": 2,
      "title": "\u0003Research gaps and needs",
      "number": "5",
      "page": 29,
      "pageLabel": "17",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-028-5-research-gaps-and-needs"
    },
    {
      "level": 3,
      "title": "Providing CAB-LA for key populations",
      "number": "5.1",
      "page": 29,
      "pageLabel": "17",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-029-51-providing-cab-la-for-key-populations"
    },
    {
      "level": 3,
      "title": "CAB-LA for adolescents under age 18",
      "number": "5.2",
      "page": 29,
      "pageLabel": "17",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-030-52-cab-la-for-adolescents-under-age-18"
    },
    {
      "level": 3,
      "title": "Safety in pregnancy and breastfeeding",
      "number": "5.3",
      "page": 30,
      "pageLabel": "18",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-031-53-safety-in-pregnancy-and-breastfeeding"
    },
    {
      "level": 3,
      "title": "Optimal HIV testing strategies and drug resistance",
      "number": "5.4",
      "page": 30,
      "pageLabel": "18",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-032-54-optimal-hiv-testing-strategies-and-drug-resis"
    },
    {
      "level": 3,
      "title": "Service delivery models",
      "number": "5.5",
      "page": 31,
      "pageLabel": "19",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-033-55-service-delivery-models"
    },
    {
      "level": 3,
      "title": "Population-level impact and costs and cost–effectiveness",
      "number": "5.6",
      "page": 32,
      "pageLabel": "20",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-034-56-population-level-impact-and-costs-and-costeff"
    },
    {
      "level": 2,
      "title": "\u0003Updating and dissemination",
      "number": "6",
      "page": 33,
      "pageLabel": "21",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-035-6-updating-and-dissemination"
    },
    {
      "level": 2,
      "title": "References",
      "number": null,
      "page": 34,
      "pageLabel": "22",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-036-references"
    },
    {
      "level": 2,
      "title": "Annex 1. \u0003Process for developing the guidelines",
      "number": null,
      "page": 37,
      "pageLabel": "25",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-037-annex-1-process-for-developing-the-guidelines"
    },
    {
      "level": 1,
      "title": "Definitions of key terms",
      "number": null,
      "page": 10,
      "pageLabel": "viii",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-002-definitions-of-key-terms"
    },
    {
      "level": 1,
      "title": "Abbreviations and acronyms",
      "number": null,
      "page": 9,
      "pageLabel": "vii",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-001-abbreviations-and-acronyms"
    },
    {
      "level": 1,
      "title": "Acknowledgements",
      "number": null,
      "page": 7,
      "pageLabel": "v",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-000-acknowledgements"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 7,
      "labelStart": "A",
      "labelEnd": "v",
      "words": 867,
      "summary": {
        "text": "The front matter of WHO's 2022 guidelines on long-acting injectable cabotegravir for HIV prevention, with ISBNs, the CC BY-NC-SA 3.0 IGO licence, suggested citation and disclaimers. It also includes the table of contents and a list of web annexes with links, such as the systematic reviews, modelling, provider survey and evidence-to-decision table.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "injectable cabotegravir",
          "heading": false
        },
        {
          "term": "long-acting injectable",
          "heading": false
        },
        {
          "term": "pre-exposure prophylaxis",
          "heading": false
        },
        {
          "term": "web annex",
          "heading": false
        },
        {
          "term": "mediation rules",
          "heading": false
        },
        {
          "term": "creative commons",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": false
        },
        {
          "term": "preferences regarding",
          "heading": false
        }
      ],
      "extract": "GUIDELINES ON LONG-ACTING INJECTABLE CABOTEGRAVIR FOR HIV PREVENTION GUIDELINES ON LONG-ACTING INJECTABLE CABOTEGRAVIR FOR HIV PREVENTION Guidelines on long-acting injectable cabotegravir for HIV prevention ISBN 978-92-4-005409-7 (electronic version) ISBN 978-92-4-005410-3 (print version) © World Health Organization 2022 Some rights reserved. This work is available under the Creative Commons Attribution-",
      "extractCut": true,
      "blocks": [
        "library/10665-360869/blocks/prose-sec-front-matter"
      ]
    },
    {
      "id": "sec-000-acknowledgements",
      "number": null,
      "title": "Acknowledgements",
      "level": 1,
      "pageStart": 7,
      "pageEnd": 9,
      "labelStart": "v",
      "labelEnd": "vii",
      "words": 825,
      "summary": {
        "text": "Acknowledges contributors to the guidelines on long-acting injectable cabotegravir, naming the Guideline Development Group co-chaired by Elizabeth Irungu and Danvic Rosadiño and other members, reviewers and WHO staff. It notes funding from PEPFAR, USAID, Unitaid and the Bill & Melinda Gates Foundation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "melinda gates",
          "heading": false
        },
        {
          "term": "paris diderot",
          "heading": false
        },
        {
          "term": "heather-marie schmidt",
          "heading": false
        },
        {
          "term": "michelle rodolph",
          "heading": false
        },
        {
          "term": "gates foundation",
          "heading": false
        },
        {
          "term": "rachel baggaley",
          "heading": false
        },
        {
          "term": "usa",
          "heading": false
        },
        {
          "term": "meg doherty",
          "heading": false
        }
      ],
      "extract": "The World Health Organization (WHO) gratefully acknowledges the contributions of many individuals and organizations to these guidelines for the use of long-acting injectable cabotegravir for HIV prevention. Guideline Development Group Co-chairs: Elizabeth Irungu (Jhpiego, Kenya) and Danvic Rosadiño (LoveYourself, Philippines). Max Appenroth (Global Action for Trans Equality, Germany), Connie Celum, (University of",
      "extractCut": true
    },
    {
      "id": "sec-001-abbreviations-and-acronyms",
      "number": null,
      "title": "Abbreviations and acronyms",
      "level": 1,
      "pageStart": 9,
      "pageEnd": 10,
      "labelStart": "vii",
      "labelEnd": "viii",
      "words": 102,
      "summary": {
        "text": "A list of abbreviations and acronyms used in the cabotegravir guidelines, such as CAB-LA, DVR, GRADE, PrEP and TDF.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hepatitis virus",
          "heading": false
        },
        {
          "term": "cabotegravir",
          "heading": false
        },
        {
          "term": "mpt",
          "heading": false
        },
        {
          "term": "multi-purpose",
          "heading": false
        },
        {
          "term": "dapivirine",
          "heading": false
        }
      ],
      "extract": "AIDS acquired immunodeficiency syndrome ART antiretroviral therapy ARV antiretroviral CAB cabotegravir CAB-LA long-acting injectable cabotegravir DTG dolutegravir DVR dapivirine vaginal ring FTC emtricitabine GDG Guideline Development Group GRADE Grading of Recommendations, Assessment, Development and Evaluation HBsAg hepatitis B surface antigen HBV hepatitis B virus HCV hepatitis C virus HIV human immunodeficiency",
      "extractCut": true
    },
    {
      "id": "sec-002-definitions-of-key-terms",
      "number": null,
      "title": "Definitions of key terms",
      "level": 1,
      "pageStart": 10,
      "pageEnd": 11,
      "labelStart": "viii",
      "labelEnd": "ix",
      "words": 406,
      "summary": {
        "text": "Defines key terms used in the guidelines, including age groups for adults, adolescents, children and infants and WHO's definition of key populations. It also explains concepts such as substantial risk of HIV and notes that risk-informed PrEP can be cost-effective but that cost should not be the only consideration.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "requesting prep",
          "heading": false
        },
        {
          "term": "hiv acquisition",
          "heading": false
        },
        {
          "term": "injectable cabotegravir",
          "heading": false
        },
        {
          "term": "long-acting injectable",
          "heading": false
        },
        {
          "term": "hiv incidence",
          "heading": false
        },
        {
          "term": "key populations",
          "heading": false
        },
        {
          "term": "age groups",
          "heading": false
        },
        {
          "term": "substantial risk",
          "heading": false
        }
      ],
      "extract": "Age groups In these guidelines the following definitions for adults, adolescents, children and infants are used in recommendations for specific age groups. It is acknowledged that countries may have other definitions under national laws. • An adult is a person older than 19 years of age. • An adolescent is a person 10–19 years of age inclusive. • A child is a person from one year of age to younger than 10 years of",
      "extractCut": true
    },
    {
      "id": "sec-003-executive-summary",
      "number": null,
      "title": "Executive summary",
      "level": 1,
      "pageStart": 11,
      "pageEnd": 11,
      "labelStart": "ix",
      "labelEnd": "ix",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-004-purpose",
      "number": null,
      "title": "Purpose",
      "level": 2,
      "pageStart": 11,
      "pageEnd": 11,
      "labelStart": "ix",
      "labelEnd": "ix",
      "words": 352,
      "summary": {
        "text": "Explains that reaching the 2025 target of 95% access to HIV prevention requires more prevention choices, recalling WHO's 2015 oral PrEP and 2021 dapivirine ring recommendations and slow uptake. It presents the guideline's purpose of recommending long-acting cabotegravir using a public health approach and highlighting implementation considerations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "long-acting injectable",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": false
        },
        {
          "term": "effective hiv",
          "heading": false
        },
        {
          "term": "dvr",
          "heading": false
        },
        {
          "term": "across variety",
          "heading": false
        },
        {
          "term": "substantial risk",
          "heading": false
        },
        {
          "term": "national guidelines",
          "heading": false
        }
      ],
      "extract": "Achieving the Global AIDS target for 2025 of ensuring that 95% of people at risk of HIV acquisition have access to HIV prevention options requires a focus on expanding effective HIV prevention choices. Pre-exposure prophylaxis (PrEP) is a key component of combination HIV prevention. In 2015 the World Health Organization (WHO) recommended oral PrEP containing tenofovir disoproxil fumarate (TDF) for people at",
      "extractCut": true
    },
    {
      "id": "sec-005-guideline-development-methodology",
      "number": null,
      "title": "Guideline development methodology",
      "level": 3,
      "pageStart": 11,
      "pageEnd": 12,
      "labelStart": "ix",
      "labelEnd": "x",
      "words": 316,
      "summary": {
        "text": "Describes how the cabotegravir recommendation was developed between January and May 2022 by WHO with a Guideline Development Group and External Review Group, based on a PICO question and systematic reviews. It states that the group judged the evidence of moderate certainty and unanimously made a conditional recommendation to offer long-acting cabotegravir as an additional prevention choice.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "conditional recommendation",
          "heading": false
        },
        {
          "term": "gdg members",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": false
        },
        {
          "term": "prevention choice",
          "heading": false
        },
        {
          "term": "methodology",
          "heading": true
        },
        {
          "term": "moderate certainty",
          "heading": false
        },
        {
          "term": "cab-la",
          "heading": false
        },
        {
          "term": "development",
          "heading": true
        }
      ],
      "extract": "In response to the availability of new evidence on the efficacy of CAB-LA for the prevention of HIV acquisition, external experts and stakeholders proposed to make this recommendation as an addition to the HIV prevention recommendations in the 2021 Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring (3). As a result, from January to May 2022, the WHO Department of Global",
      "extractCut": true
    },
    {
      "id": "sec-006-implications-for-implementation",
      "number": null,
      "title": "Implications for implementation",
      "level": 4,
      "pageStart": 12,
      "pageEnd": 13,
      "labelStart": "x",
      "labelEnd": "1",
      "words": 254,
      "summary": {
        "text": "States that long-acting cabotegravir should be offered alongside oral PrEP and the dapivirine ring within comprehensive prevention, noting that provision has so far been mostly limited to trials. It lists implementation considerations and research needs, such as HIV testing strategies, service delivery models, drug resistance, safety in pregnancy and cost-effectiveness, with full community participation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cab-la",
          "heading": false
        },
        {
          "term": "operational research",
          "heading": false
        },
        {
          "term": "differentiated service",
          "heading": false
        },
        {
          "term": "service delivery",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": false
        },
        {
          "term": "delivery models",
          "heading": false
        },
        {
          "term": "additional choice",
          "heading": false
        },
        {
          "term": "implementation",
          "heading": true
        }
      ],
      "extract": "CAB-LA should be delivered as an additional choice alongside other PrEP options, including oral PrEP and the DVR, as part of a comprehensive HIV prevention approach. To date, provision of CAB-LA has largely been limited to trial settings, certain geographies and specific populations. This guideline outlines operational research needed to address research and implementation gaps, and to inform decisions on how to",
      "extractCut": true
    },
    {
      "id": "sec-007-1-introduction",
      "number": "1",
      "title": "\u0003Introduction",
      "level": 2,
      "pageStart": 13,
      "pageEnd": 13,
      "labelStart": "1",
      "labelEnd": "1",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-008-11-background",
      "number": "1.1",
      "title": "\u0003Background",
      "level": 3,
      "pageStart": 13,
      "pageEnd": 14,
      "labelStart": "1",
      "labelEnd": "2",
      "words": 738,
      "summary": {
        "text": "Describes the global HIV situation, with about 37.7 million people living with HIV and 1.5 million new infections in 2020, a decline well short of global targets, and high shares among key populations and young women in sub-Saharan Africa. It recalls the 2021 Political Declaration targets and WHO's existing PrEP recommendations. It explains the case for additional PrEP options and notes that risk-informed PrEP can be cost-effective while having value beyond cost.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prep options",
          "heading": false
        },
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "additional prep",
          "heading": false
        },
        {
          "term": "hiv acquisition",
          "heading": false
        },
        {
          "term": "hiv infections",
          "heading": false
        },
        {
          "term": "long-acting injectable",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": false
        },
        {
          "term": "substantial risk",
          "heading": false
        }
      ],
      "extract": "HIV remains a major public health issue, with approximately 37.7 [30.2–45.1] million people living with HIV and 1.5 [1.0–2.0] million new infections in 2020. Despite global commitments to reduce new infections by 75% between 2010 and 2020, to fewer than 500 000, new HIV infections declined only by 31% over that decade (4). Key populations1 and their partners accounted for 65% of the new infections globally and for",
      "extractCut": true
    },
    {
      "id": "sec-009-12-objective-and-intended-audience",
      "number": "1.2",
      "title": "\u0003Objective and intended audience",
      "level": 4,
      "pageStart": 14,
      "pageEnd": 15,
      "labelStart": "2",
      "labelEnd": "3",
      "words": 143,
      "summary": {
        "text": "Sets out the objective of providing an evidence-informed recommendation on cabotegravir as PrEP and names the intended audiences, from national programme managers and clinicians in low- and middle-income countries to people at risk, community organizations and donors.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv prevention",
          "heading": false
        },
        {
          "term": "audience",
          "heading": true
        },
        {
          "term": "prep",
          "heading": false
        },
        {
          "term": "intended",
          "heading": true
        },
        {
          "term": "guideline",
          "heading": false
        }
      ],
      "extract": "This guideline is intended to provide an evidence-informed recommendation for CAB-LA as PrEP for HIV prevention to support countries in achieving national targets of reducing new HIV infections. The primary audience for this guideline is national and subnational programme managers and policy-makers responsible for the national health sector response to HIV, particularly in LMICs, and clinicians and other health care",
      "extractCut": true
    },
    {
      "id": "sec-010-13-guiding-principles",
      "number": "1.3",
      "title": "\u0003Guiding principles",
      "level": 4,
      "pageStart": 15,
      "pageEnd": 16,
      "labelStart": "3",
      "labelEnd": "4",
      "words": 231,
      "summary": {
        "text": "Lists the guiding principles for implementing the cabotegravir guideline, including a public health and universal health coverage approach, equity and human rights, voluntary and stigma-free services. It also stresses adapting to local context and full participation of affected communities.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prep services",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": false
        },
        {
          "term": "principles",
          "heading": true
        },
        {
          "term": "guideline",
          "heading": false
        },
        {
          "term": "informed",
          "heading": false
        },
        {
          "term": "environment",
          "heading": false
        },
        {
          "term": "implementation",
          "heading": false
        }
      ],
      "extract": "The following principles have informed the development of this guideline and should guide the implementation of the recommendations: • This guideline needs to be implemented within a public health and universal health coverage framework. In addition to strengthening HIV prevention services, the guideline should be implemented with a view to strengthening broader health systems, especially primary and community-based",
      "extractCut": true
    },
    {
      "id": "sec-011-2-methods-for-guideline-development",
      "number": "2",
      "title": "\u0003Methods for guideline development",
      "level": 2,
      "pageStart": 16,
      "pageEnd": 17,
      "labelStart": "4",
      "labelEnd": "5",
      "words": 230,
      "summary": {
        "text": "Explains that the guideline followed WHO Guidelines Review Committee procedures and the GRADE approach, with declarations of interest from all external contributors. It lists the web annexes of evidence prepared and presented at meetings facilitated by an independent methodologist.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "web annex",
          "heading": false
        },
        {
          "term": "web annexes",
          "heading": false
        },
        {
          "term": "guideline",
          "heading": true
        },
        {
          "term": "systematic review",
          "heading": false
        },
        {
          "term": "development",
          "heading": true
        },
        {
          "term": "gdg",
          "heading": false
        },
        {
          "term": "interests",
          "heading": false
        }
      ],
      "extract": "This guideline was developed in accordance with procedures established by the WHO Guidelines Review Committee (16). The recommendation in this guideline is based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to reviewing evidence and formulating recommendations (17). Consistent with previous WHO guidelines, this guideline is based on a public health approach that considers",
      "extractCut": true
    },
    {
      "id": "sec-012-3-rationale-and-supporting-evidence",
      "number": "3",
      "title": "\u0003Rationale and supporting evidence",
      "level": 2,
      "pageStart": 17,
      "pageEnd": 17,
      "labelStart": "5",
      "labelEnd": "5",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-013-31-summary-of-review-findings",
      "number": "3.1",
      "title": "Summary of review findings",
      "level": 3,
      "pageStart": 17,
      "pageEnd": 20,
      "labelStart": "5",
      "labelEnd": "8",
      "words": 2201,
      "summary": {
        "text": "Summarizes the systematic review of four randomized trials of long-acting cabotegravir, the efficacy studies HPTN 083 and 084 and the safety studies ECLAIR and HPTN 077, enrolling about 8,120 people. It reports a 79% reduction in HIV risk compared with oral TDF/FTC, largely explained by poor adherence to daily pills, and describes breakthrough and other infections. It reviews modelling for Atlanta, Montreal, South Africa and sub-Saharan Africa on the infections that expanded or switched PrEP could avert. It then covers safety, finding no significant difference in adverse events, limited pregnancy data without congenital abnormalities, and no reported differences in STIs.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cab-la arm",
          "heading": false
        },
        {
          "term": "tdf ftc",
          "heading": false
        },
        {
          "term": "cab-la arms",
          "heading": false
        },
        {
          "term": "hptn enrolled",
          "heading": false
        },
        {
          "term": "cab arm",
          "heading": false
        },
        {
          "term": "across hptn",
          "heading": false
        },
        {
          "term": "hptn found",
          "heading": false
        },
        {
          "term": "injectable cab-la",
          "heading": false
        }
      ],
      "extract": "Evidence on the safety, efficacy and effectiveness of CAB-LA was collected in a systematic review of research on CAB-LA (Web Annex B) and from additional unpublished preliminary results from modelling presented to the GDG (18, 19). The systematic review included 12 eligible articles or conference abstracts reporting data from four studies. Two studies, HPTN 083 and HPTN 084, were phase IIb/III studies assessing the",
      "extractCut": true
    },
    {
      "id": "sec-014-32-costeffectiveness",
      "number": "3.2",
      "title": "Cost–effectiveness",
      "level": 4,
      "pageStart": 20,
      "pageEnd": 21,
      "labelStart": "8",
      "labelEnd": "9",
      "words": 341,
      "summary": {
        "text": "Reviews seven costing studies, mostly from South Africa, and new models showing mixed results on whether long-acting cabotegravir is cost-effective. It finds it could be cost-effective in some settings or groups, for example in South Africa if focused on periods of substantial risk and priced within twice the cost of oral PrEP, but not compared with generic oral PrEP in high-income settings.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cost effectiveness",
          "heading": true
        },
        {
          "term": "injectable prep",
          "heading": false
        },
        {
          "term": "long-acting prep",
          "heading": false
        },
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "cab-la",
          "heading": false
        },
        {
          "term": "complementary products",
          "heading": false
        },
        {
          "term": "south africa",
          "heading": false
        },
        {
          "term": "cost-effective",
          "heading": false
        }
      ],
      "extract": "Evidence on cost–effectiveness of CAB-LA was derived from a systematic review (Web Annex B) and additional modelling evidence presented to the GDG (Web Annexes D and E) (19, 23). The review identified seven studies that assessed the cost or cost–effectiveness of CAB-LA or long-acting PrEP more generally. Of these, six modelled data and scenarios specific to South Africa (28-33), while one study assessed costs for",
      "extractCut": true
    },
    {
      "id": "sec-015-33-values-and-preferences",
      "number": "3.3",
      "title": "Values and preferences",
      "level": 4,
      "pageStart": 21,
      "pageEnd": 22,
      "labelStart": "9",
      "labelEnd": "10",
      "words": 354,
      "summary": {
        "text": "Summarizes evidence on acceptability and preferences from a review of 99 studies, key population networks and a provider survey, showing general interest in injectable PrEP with variation between groups. It notes providers' concerns about cost, workload, testing, drug resistance and stopping the drug, and the potential to overcome adherence problems with daily pills.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "injectable prep",
          "heading": false
        },
        {
          "term": "prep providers",
          "heading": false
        },
        {
          "term": "prep presents",
          "heading": false
        },
        {
          "term": "preferences",
          "heading": true
        },
        {
          "term": "cab-la",
          "heading": false
        },
        {
          "term": "web annex",
          "heading": false
        },
        {
          "term": "values",
          "heading": true
        },
        {
          "term": "studies examined",
          "heading": false
        }
      ],
      "extract": "Evidence on acceptability, values and preferences for CAB-LA was derived from a systematic review of publications on injectable PrEP (Web Annex C), results of qualitative research from four global key population networks and a study on the perspectives of PrEP providers (Web Annex F). A systematic review identified 99 articles meeting inclusion criteria for the values and preferences analysis (Web Annex C). Most",
      "extractCut": true
    },
    {
      "id": "sec-016-34-feasibility",
      "number": "3.4",
      "title": "Feasibility",
      "level": 4,
      "pageStart": 22,
      "pageEnd": 22,
      "labelStart": "10",
      "labelEnd": "10",
      "words": 221,
      "summary": {
        "text": "Notes that long-acting cabotegravir has been used only in trials, among adult cisgender women and among cisgender men and transgender women who have sex with men, with no evidence yet for people under 18. It points to experience with oral PrEP and injectable contraceptives and flags the need to explore feasibility for sex workers, people who inject drugs, prisoners and transgender men.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "implemented cab-la",
          "heading": false
        },
        {
          "term": "transgender men",
          "heading": false
        },
        {
          "term": "cisgender women",
          "heading": false
        },
        {
          "term": "hptn",
          "heading": false
        },
        {
          "term": "feasibility",
          "heading": true
        },
        {
          "term": "prep",
          "heading": false
        },
        {
          "term": "population groups",
          "heading": false
        }
      ],
      "extract": "Both HPTN 083 and HPTN 084 implemented CAB-LA for PrEP in a range of countries for adult cisgender men and transgender women who have sex with men and for cisgender women at risk of HIV. No studies have demonstrated the feasibility of this intervention in individuals under the age of 18 years, although studies are ongoing. The RCTs have continued as unblinded, open-label extensions, but no study or project has",
      "extractCut": true
    },
    {
      "id": "sec-017-35-equity",
      "number": "3.5",
      "title": "Equity",
      "level": 3,
      "pageStart": 22,
      "pageEnd": 22,
      "labelStart": "10",
      "labelEnd": "10",
      "words": 102,
      "summary": {
        "text": "States the guideline group's view that offering cabotegravir could improve equity by reaching more people who prefer injections, but that unequal access between and within countries could widen health inequalities.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "gdg noted",
          "heading": false
        },
        {
          "term": "prep",
          "heading": false
        },
        {
          "term": "cab-la",
          "heading": false
        },
        {
          "term": "health outcomes",
          "heading": false
        }
      ],
      "extract": "HIV prevention among PrEP users will contribute to equitable health outcomes by sustaining their health and the health of their sexual partners. Access to PrEP also provides opportunities for access to sexual and reproductive health services addressing multiple health needs. Considering the evidence reviewed and its discussions, the GDG noted that offering CAB-LA as an additional PrEP option could increase equity by",
      "extractCut": true
    },
    {
      "id": "sec-018-36-rationale-for-recommendation",
      "number": "3.6",
      "title": "Rationale for recommendation",
      "level": 3,
      "pageStart": 22,
      "pageEnd": 24,
      "labelStart": "10",
      "labelEnd": "12",
      "words": 395,
      "summary": {
        "text": "States the conditional recommendation that people at substantial risk of HIV may be offered long-acting injectable cabotegravir as an extra prevention option, based on moderate-certainty evidence. It explains the group's reasoning about benefits, uncertainties and costs as a barrier, and describes people for whom it may suit, such as those valuing discretion or struggling with oral pills.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "recommendation",
          "heading": true
        },
        {
          "term": "difficulty storing",
          "heading": false
        },
        {
          "term": "conditional recommendation",
          "heading": false
        },
        {
          "term": "injectable cabotegravir",
          "heading": false
        },
        {
          "term": "prevention choice",
          "heading": false
        },
        {
          "term": "long-acting injectable",
          "heading": false
        },
        {
          "term": "gdg noted",
          "heading": false
        }
      ],
      "extract": "Recommendation Long-acting injectable cabotegravir may be offered as an additional prevention choice for people at substantial risk of HIV infection, as part of combination prevention approaches (conditional recommendation; moderate certainty of evidence). The GDG agreed that CAB-LA for PrEP could have substantial benefits, a judgment based on evidence of moderate certainty, as well as on acceptability to",
      "extractCut": true
    },
    {
      "id": "sec-019-4-implementation-considerations",
      "number": "4",
      "title": "\u0003Implementation considerations",
      "level": 2,
      "pageStart": 24,
      "pageEnd": 24,
      "labelStart": "12",
      "labelEnd": "12",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-020-41-hiv-testing-and-other-testing-requirements",
      "number": "4.1",
      "title": "HIV testing and other testing requirements",
      "level": 3,
      "pageStart": 24,
      "pageEnd": 26,
      "labelStart": "12",
      "labelEnd": "14",
      "words": 1159,
      "summary": {
        "text": "Sets out HIV testing requirements for cabotegravir, with testing before starting, before each injection and ideally after stopping, using national serology algorithms and further testing for reactive or inconclusive results. It warns that missed or delayed diagnosis during use or in the drug's long pharmacokinetic tail could lead to integrase-inhibitor resistance, and weighs the uncertain benefits, costs and practical limits of adding nucleic acid testing. It also covers hepatitis B and C considerations and states that kidney function monitoring is not required.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv testing",
          "heading": true
        },
        {
          "term": "cab-la initiation",
          "heading": false
        },
        {
          "term": "cab-la among",
          "heading": false
        },
        {
          "term": "hcv treatment",
          "heading": false
        },
        {
          "term": "hbv treatment",
          "heading": false
        },
        {
          "term": "serology assays",
          "heading": false
        },
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "nat",
          "heading": false
        }
      ],
      "extract": "As with oral PrEP and the DVR, HIV testing is required before offering CAB-LA and should also be done before each injection while using CAB-LA and, ideally, regularly after CAB-LA discontinuation. HIV testing can be conducted according to the WHO testing strategy for HIV diagnosis in people >18 months of age, using the national testing algorithm composed of quality-assured serology assays (that is, rapid diagnostic",
      "extractCut": true
    },
    {
      "id": "sec-021-42-service-delivery",
      "number": "4.2",
      "title": "Service delivery",
      "level": 4,
      "pageStart": 26,
      "pageEnd": 27,
      "labelStart": "14",
      "labelEnd": "15",
      "words": 394,
      "summary": {
        "text": "Discusses service delivery for long-acting injectable cabotegravir (CAB-LA) as HIV pre-exposure prophylaxis, noting that experience so far comes mainly from two trials while oral PrEP has been offered in many settings. It suggests that such settings, and PrEP services offering a wider package of care, could support CAB-LA, with meaningful involvement of key populations and young people.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prep services",
          "heading": false
        },
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "service delivery",
          "heading": true
        },
        {
          "term": "young people",
          "heading": false
        },
        {
          "term": "cab-la",
          "heading": false
        },
        {
          "term": "prevention services",
          "heading": false
        },
        {
          "term": "health services",
          "heading": false
        },
        {
          "term": "key populations",
          "heading": false
        }
      ],
      "extract": "CAB-LA provision to date has been limited to the two RCTs, with some further experience emerging from the unblinded open-label extensions of the RCTs. Services for oral PrEP, however, have been implemented in a range of settings in many countries. These include primary health care clinics, sexual and reproductive health services, ante- and post-natal care services and in community settings through, for example, key",
      "extractCut": true
    },
    {
      "id": "sec-022-43-comprehensive-services",
      "number": "4.3",
      "title": "Comprehensive services",
      "level": 3,
      "pageStart": 27,
      "pageEnd": 27,
      "labelStart": "15",
      "labelEnd": "15",
      "words": 97,
      "summary": {
        "text": "Recommends offering PrEP, including CAB-LA, alongside other prevention and health services such as condoms, PEP, STI and hepatitis care, mental health support, gender-affirming care and harm reduction.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "services",
          "heading": true
        },
        {
          "term": "health services",
          "heading": false
        },
        {
          "term": "chemsex",
          "heading": false
        },
        {
          "term": "prep",
          "heading": false
        }
      ],
      "extract": "PrEP, including CAB-LA, should be provided in combination with other effective and well- established prevention approaches and health services. Depending on the local context and the needs and preferences of the populations that could benefit from PrEP, this may include the provision of condoms, post-exposure prophylaxis (PEP) for HIV, testing and treatment of STIs and viral hepatitis, sexual and reproductive health",
      "extractCut": true
    },
    {
      "id": "sec-023-44-offering-a-choice-of-prep-options",
      "number": "4.4",
      "title": "Offering a choice of PrEP options",
      "level": 3,
      "pageStart": 27,
      "pageEnd": 27,
      "labelStart": "15",
      "labelEnd": "15",
      "words": 76,
      "summary": {
        "text": "Advises that a range of PrEP options, including oral PrEP, the dapivirine ring and CAB-LA, be available, with counselling so people can make an informed choice.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prep",
          "heading": true
        },
        {
          "term": "options",
          "heading": true
        },
        {
          "term": "choice",
          "heading": true
        }
      ],
      "extract": "People who could benefit from PrEP have diverse HIV prevention needs and preferences, and these may change over time. A range of PrEP options should be available to provide choice to people who could benefit from PrEP, including TDF-based oral PrEP, the DVR and CAB-LA. People interested in PrEP should be provided information on the available options and their relative efficacy and safety and counselled to make an",
      "extractCut": true
    },
    {
      "id": "sec-024-45-involving-communities",
      "number": "4.5",
      "title": "Involving communities",
      "level": 3,
      "pageStart": 27,
      "pageEnd": 27,
      "labelStart": "15",
      "labelEnd": "15",
      "words": 169,
      "summary": {
        "text": "Lists good participatory practices for involving communities in PrEP and CAB-LA programmes, such as funding community-led organizations, building their capacity and expanding community-based services. It also calls for coercion-free choice and for decriminalizing consensual sex, gender expression, sex work and drug use.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "key populations",
          "heading": false
        },
        {
          "term": "communities",
          "heading": true
        },
        {
          "term": "substantial risk",
          "heading": false
        },
        {
          "term": "prep",
          "heading": false
        },
        {
          "term": "priority",
          "heading": false
        },
        {
          "term": "community-based",
          "heading": false
        }
      ],
      "extract": "Meeting the needs of populations at substantial risk of HIV infection and providing PrEP services, including CAB-LA, requires the full participation of communities in developing and implementing programmes. The following are good participatory practices that apply to services for all priority and key populations: • Recognize the leadership and resilience of priority and key populations in addressing the HIV epidemic",
      "extractCut": true
    },
    {
      "id": "sec-025-46-creating-awareness-and-demand",
      "number": "4.6",
      "title": "Creating awareness and demand",
      "level": 3,
      "pageStart": 27,
      "pageEnd": 28,
      "labelStart": "15",
      "labelEnd": "16",
      "words": 123,
      "summary": {
        "text": "Recommends awareness programmes for communities and providers before and during the introduction of CAB-LA, engaging key population networks to build acceptance and demand.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prep product",
          "heading": false
        },
        {
          "term": "awareness",
          "heading": true
        },
        {
          "term": "cab-la",
          "heading": false
        },
        {
          "term": "creating",
          "heading": true
        }
      ],
      "extract": "As CAB-LA is a new PrEP product, many communities and providers have limited or no awareness of it. Countries wanting to introduce CAB-LA as an additional HIV prevention option should conduct an awareness programme for communities and providers before and during introduction as a first step towards creating demand and enabling people to make informed choices. Engagement with networks of individuals who could benefit",
      "extractCut": true
    },
    {
      "id": "sec-026-47-adherence-support-and-discontinuation",
      "number": "4.7",
      "title": "Adherence support and discontinuation",
      "level": 3,
      "pageStart": 28,
      "pageEnd": 28,
      "labelStart": "16",
      "labelEnd": "16",
      "words": 311,
      "summary": {
        "text": "Explains that CAB-LA and other PrEP products are meant for times when HIV risk is substantial, and that trial infections occurred mainly with delayed injections or after stopping. It describes the declining protection during the drug's pharmacokinetic tail, the associated resistance risk and counselling on injection-site reactions and other side-effects.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cab concentrations",
          "heading": false
        },
        {
          "term": "cab-la",
          "heading": false
        },
        {
          "term": "discontinuation",
          "heading": true
        },
        {
          "term": "prep users",
          "heading": false
        },
        {
          "term": "prep products",
          "heading": false
        },
        {
          "term": "side effects",
          "heading": false
        },
        {
          "term": "hiv acquisition",
          "heading": false
        },
        {
          "term": "acquire hiv",
          "heading": false
        }
      ],
      "extract": "PrEP products, including CAB-LA, should be used during periods of substantial HIV risk and may be stopped if an individual is no longer at risk or decides to use an alternative PrEP product or HIV prevention strategy. The two RCTs on CAB-LA found CAB-LA highly effective at preventing HIV when CAB-LA was administered on time, although a few cases of HIV acquisition, despite on-time injections, were observed. Several",
      "extractCut": true
    },
    {
      "id": "sec-027-48-training-and-support-for-providers",
      "number": "4.8",
      "title": "Training and support for providers",
      "level": 4,
      "pageStart": 28,
      "pageEnd": 29,
      "labelStart": "16",
      "labelEnd": "17",
      "words": 236,
      "summary": {
        "text": "Describes the training providers will need to deliver CAB-LA, building on oral PrEP experience, including discussing prevention preferences, administering injections and offering respectful, non-judgemental services. It anticipates that training needs will become clearer as implementation expands.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "providers",
          "heading": true
        },
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "cab-la",
          "heading": false
        },
        {
          "term": "training",
          "heading": true
        },
        {
          "term": "service providers",
          "heading": false
        },
        {
          "term": "prevention options",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": false
        },
        {
          "term": "respectful",
          "heading": false
        }
      ],
      "extract": "As CAB-LA is a new PrEP product, few PrEP providers will have experience delivering CAB- LA. However, there is extensive experience with delivering oral PrEP. National programmes should provide training and support to a range of providers in services that may be able to offer CAB-LA to clients. Training for providers will include capacity building on discussing HIV prevention needs and preferences with clients;",
      "extractCut": true
    },
    {
      "id": "sec-028-5-research-gaps-and-needs",
      "number": "5",
      "title": "\u0003Research gaps and needs",
      "level": 2,
      "pageStart": 29,
      "pageEnd": 29,
      "labelStart": "17",
      "labelEnd": "17",
      "words": 43,
      "summary": {
        "text": "Calls for operational research, designed with affected communities, to guide CAB-LA implementation and scale-up.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "research",
          "heading": true
        },
        {
          "term": "cab-la",
          "heading": false
        },
        {
          "term": "inform",
          "heading": false
        }
      ],
      "extract": "Operational research is needed to inform decisions on the implementation and scale-up of CAB-LA. It is important to partner with communities of populations affected by HIV to identify priorities and to inform the design and implementation of research and the monitoring of outcomes.",
      "extractCut": false
    },
    {
      "id": "sec-029-51-providing-cab-la-for-key-populations",
      "number": "5.1",
      "title": "Providing CAB-LA for key populations",
      "level": 3,
      "pageStart": 29,
      "pageEnd": 29,
      "labelStart": "17",
      "labelEnd": "17",
      "words": 319,
      "summary": {
        "text": "Identifies research gaps for CAB-LA among key populations, noting that trials included few transgender men or non-binary people and no people who use drugs. It highlights needs such as data on gender-affirming hormones, alternative injection sites and monitoring of access barriers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cab-la",
          "heading": true
        },
        {
          "term": "key populations",
          "heading": true
        },
        {
          "term": "evaluate cab-la",
          "heading": false
        },
        {
          "term": "cab-la service",
          "heading": false
        },
        {
          "term": "operational research",
          "heading": false
        },
        {
          "term": "among key",
          "heading": false
        },
        {
          "term": "further research",
          "heading": false
        },
        {
          "term": "hptn",
          "heading": false
        }
      ],
      "extract": "HPTN 083 and HPTN 084 provided PrEP to cisgender men who have sex with men, transgender women (approximately 2.5% of participants) and cisgender women. However, the studies included few transgender men and did not specify including non-binary individuals. Further research is required to evaluate CAB-LA service delivery for trans and gender-diverse people and their specific needs and preferences. The trials on CAB-LA",
      "extractCut": true
    },
    {
      "id": "sec-030-52-cab-la-for-adolescents-under-age-18",
      "number": "5.2",
      "title": "CAB-LA for adolescents under age 18",
      "level": 3,
      "pageStart": 29,
      "pageEnd": 30,
      "labelStart": "17",
      "labelEnd": "18",
      "words": 163,
      "summary": {
        "text": "Notes that people under 18 were excluded from the main CAB-LA trials and that adolescent studies are planned, calling for operational research on acceptability and support for young people.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cab-la",
          "heading": true
        },
        {
          "term": "hptn",
          "heading": false
        },
        {
          "term": "young people",
          "heading": false
        },
        {
          "term": "age",
          "heading": true
        },
        {
          "term": "adolescent",
          "heading": false
        }
      ],
      "extract": "Individuals under age 18 were not included in ECLAIR, HPTN 077, HPTN 083 or HPTN 084, although sizable numbers of study participants were under the age of 30. Small numbers of adolescents have been included in ongoing sub-studies for HPTN 083 (38) and 084 (39). Additional studies including adolescent and young people are planned. These will contribute evidence on CAB-LA safety and acceptability among adolescent men",
      "extractCut": true
    },
    {
      "id": "sec-031-53-safety-in-pregnancy-and-breastfeeding",
      "number": "5.3",
      "title": "Safety in pregnancy and breastfeeding",
      "level": 3,
      "pageStart": 30,
      "pageEnd": 30,
      "labelStart": "18",
      "labelEnd": "18",
      "words": 258,
      "summary": {
        "text": "Discusses limited data on CAB-LA safety in pregnancy and breastfeeding, noting trial contraception requirements and the open-label extension allowing continued use under monitoring. It calls for further research and links to contraceptive and antenatal services.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "pregnancy",
          "heading": true
        },
        {
          "term": "breastfeeding",
          "heading": true
        },
        {
          "term": "during pregnancy",
          "heading": false
        },
        {
          "term": "hptn",
          "heading": false
        },
        {
          "term": "become pregnant",
          "heading": false
        },
        {
          "term": "cab-la",
          "heading": false
        },
        {
          "term": "women",
          "heading": false
        },
        {
          "term": "contraceptive",
          "heading": false
        }
      ],
      "extract": "In some settings pregnancy and the postpartum period are characterized by increased risk of acquiring HIV. HIV acquired during pregnancy or breastfeeding is associated with a risk of HIV transmission to the infant. It is important that women of reproductive potential do not face barriers to uptake of effective HIV prevention options such as CAB-LA. All women enrolled in HPTN 084 and HPTN 077 were required to use a",
      "extractCut": true
    },
    {
      "id": "sec-032-54-optimal-hiv-testing-strategies-and-drug-resis",
      "number": "5.4",
      "title": "Optimal HIV testing strategies and drug resistance",
      "level": 3,
      "pageStart": 30,
      "pageEnd": 31,
      "labelStart": "18",
      "labelEnd": "19",
      "words": 599,
      "summary": {
        "text": "Identifies uncertainty about optimal HIV testing strategies during CAB-LA use as a critical research gap, including risks of delayed diagnosis and drug resistance. It calls for studies on testing frequency, alternative assays and cross-resistance between cabotegravir and dolutegravir.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "drug resistance",
          "heading": true
        },
        {
          "term": "hiv drug",
          "heading": true
        },
        {
          "term": "hiv testing",
          "heading": true
        },
        {
          "term": "testing strategies",
          "heading": true
        },
        {
          "term": "cab-la implementation",
          "heading": false
        },
        {
          "term": "same-day initiation",
          "heading": false
        },
        {
          "term": "testing frequency",
          "heading": false
        },
        {
          "term": "acquired hiv",
          "heading": false
        }
      ],
      "extract": "As noted in section 4.1, the optimal HIV testing strategies, testing frequency and general approaches throughout CAB-LA implementation remain uncertain and constitute a critical research gap. Some key issues include (1) risk of delayed HIV diagnosis and treatment, (2) implications for HIV drug resistance, (3) optimal strategies for establishing HIV infection post- CAB-LA initiation and (4) feasibility and",
      "extractCut": true
    },
    {
      "id": "sec-033-55-service-delivery-models",
      "number": "5.5",
      "title": "Service delivery models",
      "level": 3,
      "pageStart": 31,
      "pageEnd": 32,
      "labelStart": "19",
      "labelEnd": "20",
      "words": 300,
      "summary": {
        "text": "Notes that oral PrEP is delivered through varied services with task sharing, whereas CAB-LA has so far been used only in trials. It calls for implementation research on offering CAB-LA alongside other options, including different injection schedules, self-injection and community delivery.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prep services",
          "heading": false
        },
        {
          "term": "cab-la",
          "heading": false
        },
        {
          "term": "lay providers",
          "heading": false
        },
        {
          "term": "delivery",
          "heading": true
        },
        {
          "term": "health care",
          "heading": false
        },
        {
          "term": "range",
          "heading": false
        },
        {
          "term": "hiv prevention",
          "heading": false
        },
        {
          "term": "models",
          "heading": true
        }
      ],
      "extract": "Oral PrEP has been delivered through a range of services, including services for STIs and sexual and reproductive health, antenatal and postnatal care and primary health care, and in a range of settings, including clinics, pharmacies and the community. Task sharing among a range of health care providers, such as nurses and trained lay providers, is playing an increasingly prominent role in the delivery of PrEP. This",
      "extractCut": true
    },
    {
      "id": "sec-034-56-population-level-impact-and-costs-and-costeff",
      "number": "5.6",
      "title": "Population-level impact and costs and cost–effectiveness",
      "level": 3,
      "pageStart": 32,
      "pageEnd": 33,
      "labelStart": "20",
      "labelEnd": "21",
      "words": 172,
      "summary": {
        "text": "Reports preliminary modelling suggesting that expanding total PrEP use has the largest effect on HIV incidence and that CAB-LA could be cost-effective in sub-Saharan Africa, while calling for more realistic models and cost studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cost effectiveness",
          "heading": true
        },
        {
          "term": "oral prep",
          "heading": false
        },
        {
          "term": "cab-la",
          "heading": false
        },
        {
          "term": "population-level",
          "heading": true
        },
        {
          "term": "impact",
          "heading": true
        },
        {
          "term": "suggest",
          "heading": false
        }
      ],
      "extract": "effectiveness Preliminary results of mathematical modelling suggest that increasing the total number of PrEP users, whether of oral PrEP or CAB-LA, has the strongest impact on decreasing HIV incidence (Web Annexes D and E) (23). CAB-LA use itself has the potential to increase the number of HIV infections averted. Models for sub-Saharan Africa also suggest that CAB-LA could be cost-effective even if priced higher",
      "extractCut": true
    },
    {
      "id": "sec-035-6-updating-and-dissemination",
      "number": "6",
      "title": "\u0003Updating and dissemination",
      "level": 2,
      "pageStart": 33,
      "pageEnd": 34,
      "labelStart": "21",
      "labelEnd": "22",
      "words": 228,
      "summary": {
        "text": "Describes how the CAB-LA guideline will be published online with its web annexes, incorporated into WHO's consolidated HIV guidelines and disseminated with regional and country offices, with uptake tracked through a country policy database.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "dissemination",
          "heading": true
        },
        {
          "term": "consolidated guidelines",
          "heading": false
        },
        {
          "term": "implementing partners",
          "heading": false
        },
        {
          "term": "adaptation",
          "heading": false
        },
        {
          "term": "updates",
          "heading": false
        },
        {
          "term": "conducting",
          "heading": false
        },
        {
          "term": "country",
          "heading": false
        }
      ],
      "extract": "This guideline is being launched as a web-based product for dissemination and will include all evidence as presented to the GDG (Web Annexes A to F). The guideline will also be incorporated into the periodic updates of the WHO consolidated guidelines on HIV (3). The consolidated guidelines on HIV will be updated in full or in part based on regular scoping exercises of available evidence and experience from country",
      "extractCut": true
    },
    {
      "id": "sec-036-references",
      "number": null,
      "title": "References",
      "level": 2,
      "pageStart": 34,
      "pageEnd": 37,
      "labelStart": "22",
      "labelEnd": "25",
      "words": 1319,
      "summary": {
        "text": "The reference list for the WHO guidelines on long-acting injectable cabotegravir for HIV prevention, citing WHO HIV guidance, UNAIDS reports and trial registrations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "long-acting cabotegravir",
          "heading": false
        },
        {
          "term": "injectable cabotegravir",
          "heading": false
        },
        {
          "term": "pre-exposure prophylaxis",
          "heading": false
        },
        {
          "term": "preexposure prophylaxis",
          "heading": false
        },
        {
          "term": "hiv pre-exposure",
          "heading": false
        },
        {
          "term": "choice experiment",
          "heading": false
        },
        {
          "term": "accessed june",
          "heading": false
        },
        {
          "term": "cabrera escobar",
          "heading": false
        }
      ],
      "extract": "1. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015 (https://apps.who.int/iris/handle/10665/186275, accessed 18 May 2022). 2. Guidelines: updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. Geneva: World Health Organization; 2021 (https://apps.who.int/ iris/handle/10665/340190,",
      "extractCut": true
    },
    {
      "id": "sec-037-annex-1-process-for-developing-the-guidelines",
      "number": null,
      "title": "Annex 1. \u0003Process for developing the guidelines",
      "level": 2,
      "pageStart": 37,
      "pageEnd": 40,
      "labelStart": "25",
      "labelEnd": "28",
      "words": 1097,
      "summary": {
        "text": "An annex describing how the CAB-LA guideline was developed under WHO guideline standards and Guideline Review Committee oversight, coordinated by the Department of Global HIV, Hepatitis and STI Programmes. It outlines the systematic review of safety and efficacy, supplementary evidence on values, costs and feasibility, and how the Guideline Development Group reached its recommendation. The annex closes with contact details and the ISBN.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "injectable cabotegravir",
          "heading": false
        },
        {
          "term": "long-acting injectable",
          "heading": false
        },
        {
          "term": "gdg meeting",
          "heading": false
        },
        {
          "term": "hiv modelling",
          "heading": false
        },
        {
          "term": "undesirable effects",
          "heading": false
        },
        {
          "term": "external review",
          "heading": false
        },
        {
          "term": "modelling consortium",
          "heading": false
        },
        {
          "term": "desirable effects",
          "heading": false
        }
      ],
      "extract": "ANNEX. \u0003PROCESS FOR DEVELOPING THE GUIDELINES Methods for synthesizing evidence WHO’s Department of Global HIV, Hepatitis and STI Programmes developed this guideline according to WHO standards and requirements for guideline development, 2nd edition, 2014 (1) and under the oversight of the WHO Guideline Review Committee. The Secretariat within the WHO Department of Global HIV, Hepatitis and STI Programmes coordinated",
      "extractCut": true
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 0,
        "items": []
      },
      "found_not_listed": {
        "count": 10,
        "items": [
          "5 Research gaps and needs\b",
          "6 Updating and dissemination\b",
          "5 \u0003RESEARCH GAPS AND NEEDS",
          "5.1 Providing CAB-LA for key populations",
          "5.2 CAB-LA for adolescents under age 18",
          "5.3 Safety in pregnancy and breastfeeding",
          "5.4 Optimal HIV testing strategies and drug resistance",
          "5.5 Service delivery models",
          "5.6 Population-level impact and costs and cost– effectiveness",
          "6 \u0003UPDATING AND DISSEMINATION"
        ]
      },
      "page_mismatch": {
        "count": 0,
        "items": []
      }
    },
    "figureSequenceGaps": [],
    "pageLabelConflicts": {
      "count": 0,
      "items": []
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "injectable cab-la",
      "heading": false
    },
    {
      "term": "injectable prep",
      "heading": false
    },
    {
      "term": "long-acting prep",
      "heading": false
    },
    {
      "term": "cab-la services",
      "heading": false
    },
    {
      "term": "cab-la implementation",
      "heading": false
    },
    {
      "term": "cab-la among",
      "heading": false
    },
    {
      "term": "cab-la injections",
      "heading": false
    },
    {
      "term": "during cab-la",
      "heading": false
    },
    {
      "term": "found cab-la",
      "heading": false
    },
    {
      "term": "offering cab-la",
      "heading": false
    },
    {
      "term": "oral prep",
      "heading": false
    },
    {
      "term": "receiving cab-la",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": "A",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 2,
      "label": "B",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "i",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "ii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 5,
      "label": "iii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 6,
      "label": "iv",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 7,
      "label": "v",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 8,
      "label": "vi",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 9,
      "label": "vii",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 10,
      "label": "viii",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 11,
      "label": "ix",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 12,
      "label": "x",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 13,
      "label": "1",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 14,
      "label": "2",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 15,
      "label": "3",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 16,
      "label": "4",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 17,
      "label": "5",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 18,
      "label": "6",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 19,
      "label": "7",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 20,
      "label": "8",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 21,
      "label": "9",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 22,
      "label": "10",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 23,
      "label": "11",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 24,
      "label": "12",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 25,
      "label": "13",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 26,
      "label": "14",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 27,
      "label": "15",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 28,
      "label": "16",
      "source": "pdf-labels",
      "confidence": 1
    },
    {
      "physical": 29,
      "label": "17",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 30,
      "label": "18",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 31,
      "label": "19",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 32,
      "label": "20",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 33,
      "label": "21",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 34,
      "label": "22",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 35,
      "label": "23",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 36,
      "label": "24",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 37,
      "label": "25",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 38,
      "label": "26",
      "source": "pdf-labels",
      "confidence": 0.85
    },
    {
      "physical": 39,
      "label": "27",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 40,
      "label": "28",
      "source": "pdf-labels",
      "confidence": 0.7
    }
  ],
  "figures": [
    {
      "kind": "box",
      "number": "1",
      "title": "A note on substantial risk of HIV acquisition",
      "page": 14,
      "pageLabel": "2",
      "confidence": 0.6,
      "evidence": [
        "in-sequence"
      ]
    }
  ],
  "images": [
    {
      "id": "img-p040-1",
      "file": "images/img-p040-1.webp",
      "page": 40,
      "narratives": {
        "en": "An ISBN barcode with the number 9789240054097 printed above and below the bars.",
        "ar": "رمز شريطي للرقم الدولي المعياري للكتاب (ISBN) يحمل الرقم 9789240054097 مطبوعاً أعلى الأشرطة وأسفلها.",
        "zh": "国际标准书号（ISBN）条形码，条码上方和下方印有编号9789240054097。",
        "es": "Código de barras ISBN con el número 9789240054097 impreso encima y debajo de las barras.",
        "fr": "Code-barres ISBN portant le numéro 9789240054097 imprimé au-dessus et au-dessous des barres.",
        "ru": "Штрихкод ISBN с номером 9789240054097, напечатанным над штрихами и под ними."
      },
      "state": "draft"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 38,
      "note": "outline"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 39,
      "note": "4 levels"
    },
    {
      "kind": "figures",
      "state": "found",
      "count": 1
    },
    {
      "kind": "tables",
      "state": "not-extracted"
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p34); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "not-extracted",
      "note": "a glossary section is in the text (p9); its entries are not extracted"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "partial",
      "count": 35,
      "note": "35 of 39 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-360869"
  }
}
